Tafamidis ATTR denied as non-formulary by Humana?

Humana's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Tafamidis as Non-Formulary — and What You Can Do

Humana's formulary is a tiered list of covered drugs. Tafamidis may be excluded from the formulary, placed on a tier requiring separate authorization, or omitted from certain plan designs entirely. A non-formulary denial is a coverage-structure decision, not a clinical judgment about whether the drug is appropriate. For patients with ATTR cardiomyopathy, the non-formulary pathway is particularly worth pursuing because there is no therapeutically interchangeable formulary alternative — no other approved drug works by the same mechanism or treats the same underlying disease process.

## Your Federal Appeal Rights

• ACA §2719 External Review: Available after exhausting internal appeals, within approximately four months of the final internal denial. Check your Explanation of Benefits for the precise deadline.
• ERISA §503: Employer-plan members may demand the specific formulary language and clinical rationale in writing, plus a full-and-fair review of any exception request.
• Expedited Track: If clinical urgency applies, request simultaneous expedited internal and external review — typically resolved within 72 hours.

## Concrete Appeal Steps and Timeline

1. Request a formulary exception through Humana — this is a distinct process from a standard appeal and is often faster. The prescriber must attest that no formulary alternative is medically appropriate. 2. Obtain Humana's formulary exception criteria and coverage policy for tafamidis. 3. If the formulary exception is denied, file a formal Level 1 internal appeal. 4. Ask the prescriber to request a peer-to-peer call with Humana's pharmacy or medical director — particularly effective when there is no equivalent formulary drug. 5. Escalate to Level 2 and then external IRO review if internally denied.

## Documentation to Gather

• Formulary alternative analysis: A prescriber statement identifying each formulary cardiac drug Humana might propose as an alternative and explaining specifically why each is not a therapeutic substitute for tafamidis in ATTR-CM. The distinction in mechanism and approved indication is the core argument.
• ATTR-CM diagnosis confirmation: Scintigraphy, biopsy, or genetic testing establishing the diagnosis, so the exception request is grounded in confirmed need.
• Prescriber letter of medical necessity: Should address the progressive, life-threatening nature of ATTR-CM and the absence of a formulary-equivalent disease-modifying therapy.
• Relevant guideline reference: Generic citation to ACC/AHA or HFSA society recommendations — prescriber should draft this language without citing specific study statistics.

## Criteria-Mapping Structure

Humana's formulary exception form typically requires: the diagnosis (with ICD code), the requested drug, a list of formulary alternatives considered, and the clinical reason each alternative is inadequate. Prepare a clean one-page summary covering each of these fields. Attach the diagnosis confirmation and the prescriber letter. For non-formulary appeals, the cleaner and more targeted the submission, the faster the resolution — avoid submitting unnecessary records that obscure the core argument.